Stage 4 Lung Cancer Treatment
Helping Patients Outperform Dismal Lung Cancer Statistics with Powerful Treatment Options
Most patients know lung cancer is the leading cause of cancer deaths in the U.S. for both men and women. Almost 550,000 people in the U.S. are living with lung cancer right now with an estimated 234,030 new patients expected to be diagnosed with lung cancer by the end of the year(1). This staggering statistic is due to the standardized treatment regimen's lack of personalized targets. Most major cancer institutions refer to the NCCN (National Comprehensive Cancer Network) guidelines for lung cancer treatment options for their patients. Unfortunately, the majority of lung cancer patients are unresponsive to the options recommended by the NCCN. The lack of effectiveness from the standardized treatment options is why lung cancer is a trying and complicated disease to treat. Because only 16% of lung cancer cases are caught in the early stages, most lung cancer patients are faced with an advanced, refractory to treatment, and dangerous form of cancer(1).
When conventional cancer treatment options fail, and lung cancer spreads to other organs, the five-year survival rate of patients drops from a low 18.6% to a dismal 5% and, unfortunately, more than half of those diagnosed with lung cancer will die within that first year(1). Lung cancer patients generally do not respond well to conventional oncology and with a mortality rate of more than 50% in the first year of diagnosis, it is essential to get the right treatment and to get it early enough to properly fight lung cancer. This means that testing is crucial to creating a decisive and effective treatment protocol.
ICCA's Lung Cancer Approach
At Integrative Cancer Centers of America, we are a center of excellence for personalized oncology and have been treating late-stage lung cancer for nearly two decades and have extensive experience treating stage four lung cancer patients who have been unresponsive to conventional treatment options. ICCA even treats patients who have been sent to hospice by other well-established cancer centers and are often able to achieve positive responses, even where the patient's conventional treatment options have been exhausted.
ICCA excels in late-stage lung cancer treatment because our treatment options go beyond the standardized treatment approach and utilize the latest advances in world-class oncology, immunotherapy options, and genetic targeting. We specialize in discovering the many causes of lung cancer and addresses them with researched based alternative and integrative treatment options to offer the highest level of personalized care possible to help our patients outperform.
Our approach is so advanced that often commercially available drugs are not viable for our patient's genetic cancer targets. Because we test the patient's cancer against potentially effective drug targets, we must then develop these customized treatment options in our own compounding pharmacy to meet our patients' needs. We often hear from our patients that they wish they would have come to ICCA sooner because of our unique approach to cancer care.
Lung Cancer Infectious Causes
At Integrative Cancer Centers of America we use next-generation genetic testing which can help pinpoint the medications and natural agents best suited for treating your unique form of lung cancer. The genetic testing may also reveal resistance to treatment issues your body is dealing with. By addressing the resistance to treatment, we can help reestablish the body giving you the greatest chance to respond to therapy. Most patients are not aware that lung cancer develops from other causes beside cigarette smoking, in fact many forms of lung cancer stem from infectious causes such as chlamydia pneumoniae (refer to our published paper Cancer and Infectious Causes to learn more). From our clinical experience, when infectious causes are found in our patients specialized forms of immunotherapy must be deployed. Immunotherapy is a critical piece for effective lung cancer treatment. PD1 inhibitors are helpful but not enough on their own and often other targeted forms of immunotherapy need to be deployed to improve responses.
Errors in the Standardized Lung Cancer Treatment Approach
When it comes to lung cancer, your disease is unique to you because cancer is a mutation of your specific DNA. The DNA will continue to mutate and change as the disease progresses causing the cancer itself to continue to change and mutate and become more resistant to treatments it is exposed to. Because of these factors, treating lung cancer is going to be a moving target that needs a personalized approach with extensive testing to find the medications that are going to be best for your specific cancer's targets. Conventional standard oncology is not designed to approach treatment in this way, they design their protocols based on large clinical trials, these clinical trial findings are the basis for what the NCCN prescribes as "effective" treatments for a specific type of cancer. With over 50% of patients not surviving one year past initial diagnosis, it becomes clear the conventional lung cancer treatment method isn't working for the majority.
If any cancer type needed personalization more than others, lung cancer is the prime example. The standard of care is clearly not working for lung cancer patients. Having targets properly found and addressed can make all the difference in getting a favorable response to care. It is important to note that not all genetic testing is equal, and data must be taken, not from the biopsy of the tumor, but from the circulating tumor cells and free-floating cancer DNA in the body to achieve the best treatment options and targets for the patient. ICCA is one of the only cancer centers in the world approaching lung cancer with this level of precision.
At ICCA we go beyond the standardized treatment protocols and have the freedom to build treatments based on your individual cancer expression, biomarkers, molecular profiles, and immunotherapy targets. The key to establishing these treatment options is to get extensive state-of-the-art testing to identify the treatment targets of your lung cancer and to not rely on generalized information that comes from a clinical trial. Treatment must be based on you and built specifically for you and your cancer expression, we call this style of treatment "N of 1" at ICCA. Advanced testing and unique treatments based off next-generation genetic testing is the key to success and no one in the nation can test and develop treatments at the level ICCA does.
Lung Cancer Causative Factors
When we begin treating lung cancer, we not only sequence the DNA of circulating cancer cells, but we look deeper into your causative factors that may be feeding your lung cancer. We also look at underlying infections, heavy metals, toxins, and epigenetics to identify and treat the root cause of your condition in addition to attacking the cancer cells. We have done extensive research into infectious causes of cancer and have identified Chlamydia Pneumoniae to have a causative relationship with lung cancer(2) in addition to many other environmental causes and chemical causes like radiation, asbestos, and heavy metals. Our ability to identify and properly address the causes of your lung cancer in addition to the cancer itself is an important part of giving you the best chance to respond to treatment.
Lung Cancer and Chemotherapy Options
At ICCA, we focus on many pathways for treating lung cancer to build a comprehensive protocol. We focus on individualized treatment protocols that utilize the most modern and cutting-edge medications and treatments. Our proprietary treatments use a targeted method to deliver micro doses of genetically determined chemotherapies. Standardized chemotherapy methods prescribe the largest possible dose, known as the maximum therapeutic dose, in hopes to kill the cancer. This excessive dose of chemotherapy is very hard on the patient's body and causes a laundry list of side-effects that often harm more than they may help. The effects on the immune system from administering maximum therapeutic dosed chemotherapy is devastating and may lead to cancer progression if the correct chemotherapy wasn't selected in the first round. Our proprietary treatment, Genetically Targeted Fractionated Chemotherapy, gives us the means to utilize micro doses of multiple genetically targeted chemotherapies(3). These genetically determined targeted chemotherapies will be administered in concert with an induced therapeutic window and guided cell infiltration to further target your lung cancer by promoting the cancer cells to intake the chemotherapy for maximum effect with minimum side-effects(3). We have extensive experience treating resistant and persistent cancers and Genetically Targeted Fractionated Chemotherapy can be an effective treatment for those with chemotherapy resistant cancers(3)(refer to our published paper Genetically Targeted Fractionated Chemotherapy to learn more).
Immunotherapy for Lung Cancer
Furthermore, we actively treat the immune system to aid your body in recovery while providing immunotherapy to boost your body's own ability to fight the lung cancer. We utilize our own in-house pharmacy to create not only targeted chemotherapies, but personalized custom medications of the highest quality to attack your cancer's specific targets. We have the knowledge and experience to promote detoxification and immune restoration that is unrivaled by any other clinic in the country. We can remove your antibodies and reprogram them to target the cancer cells based on biomarker information gathered from testing(4) (refer to our published paper Immunotherapy in Cancer Treatment to learn more). The body is naturally the best tool for fighting cancer, our immune system destroys countless number of cancer cells every day and by supplementing our treatments with immunotherapy and detoxification techniques we give our patients the best possibility to positively respond to treatment.
CIPI ™: A Revolutionary Precision Targeted Chemoembolization Option
ICCA's latest lung cancer treatment options can take targeted chemotherapy to the next level. CIPI ™, or Chemo Immunotherapy Percutaneous Injections is a unique form of precision tumor embolization designed to treat resistant and aggressive tumors that are fibrous and difficult to penetrate through traditional intravenous chemotherapy administration methods. CIPI ™ was created to provide advanced treatment options for patients suffering from late-stage and metastasized lung cancer where traditional chemotherapy administration is not a viable option.
CIPI ™ utilizes direct injection of genetically personalized micro-dosed medications into the tumor, potentially maximizing bioavailability of customized low-dose chemotherapy and adjunctive agents. Furthermore, the CIPI ™ procedure simultaneously delivers genetically targeted adjuvant immunotherapies that are designed to revitalize and support your unique immune system's response and potentially increase tumor kill. Finally, the targeted delivery CIPI ™ provides can potentially reduce the debilitating side-effects normally associated with aggressive chemotherapies, providing patients with a powerful cancer treatment while reducing the chances of possible negative impact of healthy cells. Late-stage or metastasized lung cancer prognoses can prove difficult to treat, and not all patients are candidates for the CIPI ™ procedure. CIPI ™ is a revolutionary technology that we believe will provide our patients with new and exciting opportunities to fight against their lung cancer expressions.
At ICCA, we combine the best options from both natural and conventional medicine to provide an all-encompassing approach to treatment and have been leading the integrative cancer field for the last two decades. We have access to a wider range of treatment options including the newest and best methods from around the world and because we are based in Scottsdale Arizona, we have access to the best integrative techniques in the nation. Our philosophy is to provide the highest quality compassionate care to our patients to help them make meaningful and life changing progress in the fight against their disease. If you or one of your loved one is struggling with lung cancer, please contact our Patient Care Coordinator team at (888) 526-6398 and let us help you fight lung cancer. May God Bless you on your journey to healing.
 Association AL. Lung Cancer Fact Sheet 2018 [updated August 21, 2018. Available from: https://www.lung.org/
 Smith AJ, Oertle J, Prato D. Cancer and Infectious Causes. Open Journal of Medical Microbiology. 2014;Vol.04No.03:17.
 Smith AJ, Oertle J, Prato D. Genetically Targeted Fractionated Chemotherapy. Journal of Cancer Therapy. 2015;Vol.06No.02:17.
 Smith AJ, Oertle J, Prato D. Immunotherapy in Cancer Treatment. Open Journal of Medical Microbiology. 2014;Vol.04No.03:14.